Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 3/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4541909 | 0.90 | KCNH2 (0.47) | MCHR1KCNH2ESR1KDRCYP1A2 | |
| SCHEMBL4534597 | 0.82 | SCN7A (0.48) | MCHR1KCNH2 | |
| SCHEMBL4540231 | 0.81 | MCHR1 (0.59) | MCHR1KCNH2 | |
| SCHEMBL4531564 | 0.81 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL4541266 | 0.81 | HRH3 (0.46) | MCHR1KCNH2 | |
| SCHEMBL4536158 | 0.79 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL4537433 | 0.76 | CYP1A2 (0.44) | MCHR1KDM4ECYP1A2SRC | |
| SCHEMBL4526576 | 0.74 | MCHR1 (0.37) | MCHR1KCNH2 | |
| SCHEMBL4534426 | 0.74 | MCHR1 (0.73) | MCHR1KCNH2 | |
| SCHEMBL13677545 | 0.72 | MCHR1 (0.38) | MCHR1KCNH2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | MCHR1 357/4885CHRNB2 1957/4885CHRNA4 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.